title: Sertraline-induced hyperglycemia: case report.
abstract: Empirical studies with humans suggest that selective serotonin reuptake inhibitors (SSRIs) may, through increases in serotonergic activity, increase insulin secretion, increase insulin sensitivity, and lower serum glucose levels. Indeed, the potentially beneficial effects of SSRI treatment in diabetics are documented. However, we describe the case of a female, with diet-controlled, type 2 diabetes, whose glucose levels increased with exposure to sertraline.
authors.affiliation: Wright State University, Dayton, Ohio, USA. Randy.sansone@kmcnetwork.org
authors.forename: Randy A
authors.initials: RA
authors.lastname: Sansone
authors.forename: Lori A
authors.initials: LA
authors.lastname: Sansone
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects*; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced*; D008875:Middle Aged; D020280:Sertraline / Q000009:adverse effects*
chemical_list: D000928:Antidepressive Agents; D020280:Sertraline